Immunovant (IMVT) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for August 12, 2024, to be held virtually, allowing broader shareholder participation and cost savings.

• Shareholders will vote on the election of three directors, ratification of the independent auditor, and a non-binding advisory vote on executive compensation.

• The record date for voting is June 18, 2024, with 146,180,134 shares of common stock and 10,000 shares of Series A preferred stock eligible to vote.

Voting matters and shareholder proposals

• Three proposals: election of directors (Peter Salzmann, George Migausky, Douglas Hughes), ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation.

• Shareholders may submit additional proposals for the 2025 annual meeting between April 14 and May 14, 2025.

• Voting can be done online, by phone, or by mail, with detailed instructions provided.

Board of directors and corporate governance

• The board consists of seven members, with four elected by Series A preferred stockholders and three by common and preferred stockholders voting together.

• The company is a "controlled company" under Nasdaq rules, relying on exemptions from certain governance requirements.

• Three directors (Hughes, Migausky, Pande) are considered independent; the board is led by Executive Chairperson Dr. Frank Torti.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities.